August 8, 2020

The Niche

Knoepfler lab stem cell blog

Month: May 2017

3 min read

A new, brief study in mice from the Vinit Mahajan lab argues CRISPR can have very large numbers of off-target sites. Their paper is entitled “Unexpected mutations after CRISPR–Cas9 editing in vivo” and was published in Nature Methods.This work has garnered a lot of attention in the media. Let’s take a journal club review kind of approach to this pub. In this paper there were two major reported findings. First, the number of reported CRISPR-associated mutations in the two mice studied (versus one control) were high, over a …Read More

4 min read

Is there a proliferating stem cell fake news problem in the biotech world? More broadly, the SEC is cracking down on the mess that is fake biotech news, but what about fake news on stem cell biotechs more specifically? Already in the past year I’ve seen examples of possible stem cell fake news. Hyped press releases (PR) that might arguably be in part fake news are nothing new and there has always been stock pumping, but another more recent phenomenon consists of more extensive series of …Read More

2 min read

Stem cells and regenerative medicine are going to have big future impact across a broad spectrum of health problems, but there are specific ways they may be of particular positive impact for our men and women in service. Here on Memorial Day I’ve focused on 5 main areas where I predict that stem cells and regenerative medicine will help our troops in the future in the biggest ways and included key links. Research on stem cell military applications has really advanced in the past …Read More

2 min read

Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial cells (RPEs) for treatment of multiple kinds of macular degeneration. These products were advancing in promising clinical trials and had demonstrated good safety profiles. After the purchase of Ocata by …Read More